IMbrave150 : A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Liver<br/>CancersCancer LocationLiver
Cancers

Systemic therapy | Stomach and upper gastrointestinal tractLiver

Trial Overview Read MoreRead more

This phase III trial is comparing two immunotherapy drugs (Atezolizumab and Bevacizumab) with an oral targeted therapy (Sorafenib) in the treatment of previously untreated locally advanced or metastatic hepatocellular (liver) cancer.
 

This trial is treating patients with Hepatocellular (Liver) Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Commercial Sponsor

Hoffmann-La Roche

Summary

Participants will be randomized into one of two arms. In the experimental arm, participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle; Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle. In the comparator arm, participants will Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle.

Recruiting Hospitals Read MoreRead more

Western Health - Sunshine Hospital
St Albans
Ms Heike Raunow
Heike.Raunow@wh.org.au
03 8395 9167

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next